CLAIM LISTING:

1. (Currently amended) A compound comprising Formula I:



I

wherein:

X is carbon or nitrogen;

Y is carbon;

and X-Y considered together are two adjoining atoms of the ring A, said ring being a fused aromatic ring of five to six atoms per ring optionally incorporating one to two heteroatoms per ring, chosen from N, O, or S; wherein, when X is nitrogen, the bond between atoms X and Y is a single bond, and when X is carbon, the bond between atoms X and Y is double bond;

Z is -C(O)-;

each R is independently selected from lower alkyl;

R^1 is selected from:

hydrogen; lower alkyl;

aryl; arylalkyl; arylaminocarbonyl; wherein the aryl group is optionally substituted with one to two substituents selected from lower alkyl, halo, cyano and lower alkoxy; and

heteroaryl or heteroarylalkyl, wherein the aryl group is optionally substituted with one or two ~~substituents~~ substituents selected from the group consisting of lower alkyl, halogen, cyano, and lower alkyl;

R^2, R^3, and R^4 are each independently in each occurrence selected from:

hydrogen; lower alkyl;

cycloalkyl or cycloalkylalkyl, wherein the cycloalkyl group is optionally substituted with one, two, or three substituents selected from the group consisting of hydroxy, cyano, lower alkyl, lower alkoxy, halo-lower alkoxy, alkylthio, halogen, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, and phenyl optionally substituted with one or two substituents selected from the group consisting of lower alkyl, halogen, cyano and lower alkoxy;

aryl or arylalkyl, wherein the aryl group is optionally substituted with one, two, or three substituents selected from the group consisting of hydroxy, cyano, lower alkyl, lower alkoxy, halogen-lower alkoxy, alkylthio, halogen, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino, and arylcarbonylamino, or two adjacent atoms of the aryl ring can be substituted with a methylenedioxy or ethylenedioxy group to form a fused heterocyclyl ring;

heterocyclyl or heterocyclylalkyl, wherein the heterocyclyl group is optionally substituted with one, two, or three substituents selected from the group consisting of hydroxy, hydroxyalkyl, oxo, cyano, cyanoalkyl, lower alkyl, lower alkoxy, alkoxyalkyl, halogen-lower alkoxy, alkylthio, halogen, haloalkyl, nitro, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, and phenyl optionally substituted with one or two substituents selected from the group consisting of lower alkyl, halogen, cyano and lower alkoxy;

heteroaryl or heteroarylalkyl, wherein the heteroaryl group is optionally substituted with one, two, or three substituents selected from the group consisting of

hydroxy, cyano, lower alkyl, lower alkoxy, halogen-lower alkoxy, alkylthio, halogen, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino, and arylcarbonylamino;

hydroxy; hydroxyalkyl; alkoxy; alkoxyalkyl;

halo; haloalkyl; cyano; cyanoalkyl; and

$-(CH_2)_{0-3}NR'R''$; $-C(=NH)-NR'R''$; $-N-C(=NR')-R''$; $-N=CR'-NR'R''$; $-SO_2NR'R''$;

$-NSO_2R'$; $-C(O)R'$; $-C(O)NR'R''$; or $-NC(O)R'$; ~~or $-N=R'''$;~~

with the proviso that if A is a benzene ring, at least one of R^2, R^3 or R^4 is not hydrogen; or

R^2 and R^3, if adjacent, taken together with the carbons to which they are attached may form a 5- to 7- membered aromatic, saturated or unsaturated ring, optionally incorporating one or two ring heteroatoms chosen from N, S, or O, which can be optionally substituted with one or two ~~substituents~~ substituents selected from lower alkyl, halo, haloalkyl, cyano, alkylthio, and lower alkoxy; and

R' and R'' are independently in each occurrence selected from:

hydrogen; lower alkyl; substituted lower alkyl;

hydroxyalkyl; alkoxyalkyl;

cycloalkyl, wherein the cycloalkyl group is optionally substituted with one, two, or three substituents selected from the group consisting of hydroxy, cyano, lower alkyl, lower alkoxy, halogen-lower alkoxy, alkylthio, halogen, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, and phenyl;

aryl or arylalkyl, wherein the aryl group is optionally substituted with one, two, or three substituents selected from the group consisting of hydroxy, cyano, lower alkyl, lower alkoxy, halogen-lower alkoxy, alkylthio, halogen, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino,

alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino, and arylcarbonylamino, or two adjacent atoms of the aryl ring can be substituted with a methylenedioxy or ethylenedioxy group to form a fused heterocyclic ring;

heteroaryl or heteroarylalkyl, wherein the heteroaryl group is optionally substituted with one, two, or three substituents selected from the group consisting of hydroxy, cyano, lower alkyl, lower alkoxy, halogen-lower alkoxy, alkylthio, halogen, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino, and arylcarbonylamino;

heterocyclyl or heterocyclylalkyl, wherein the heterocyclyl group is optionally substituted with one, two, or three substituents selected from the group consisting of hydroxy, oxo, cyano, cyanoalkyl, lower alkyl, lower alkoxy, halogen-lower alkoxy, alkylthio, halogen, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino;

or R' and R" together with the nitrogen to which they are attached may form a 5- to 7-membered ring, optionally incorporating one additional ring heteroatom chosen from N, O or S; wherein this ring is optionally substituted with one or two substituents selected from the group consisting of lower alkyl, halogen, cyano, lower alkoxy and phenyl optionally substituted with one or two substituents selected from the group consisting of lower alkyl, halogen, cyano and lower alkoxy;

~~R''' is selected from heterocyclyl optionally substituted with one or two substituents selected from the group consisting of hydroxy, oxo, cyano, cyanoalkyl, lower alkyl, and lower alkoxy;~~

or individual isomers, racemic or non-racemic mixtures of isomers or pharmaceutically acceptable salts or solvates thereof.

2. (Original) The compound of Claim 1, wherein X is carbon.

3. (Original) The compound of Claim 1, wherein X is nitrogen.

4. (Original) The compound of Claim 1, wherein R^1 is hydrogen.

5. (Original) The compound of Claim 4, wherein X is carbon and A is a fused aryl ring.

6. (Original) The compound of Claim 5, wherein A is a fused benzene ring.

7. (Original) The compound of Claim 4, wherein X is carbon and A is a fused heteroaryl ring.

8. (Original) The compound of Claim 7, wherein A is a fused pyrimidine ring.

9. (Original) The compound of Claim 7, wherein A is a fused pyrrole ring.

10. (Currently amended) The compound of Claim 9, wherein R^2 and R^3 taken together with the carbons to which they are attached form a fused benzene ring, optionally substituted with one or two ~~substitutents~~ substituents selected from lower alkyl, halo, haloalkyl, cyano, alkylthio, or lower alkoxy.

11. (Original) The compound of Claim 7, wherein A is a fused pyridine ring.

12. (Original) The compound of Claim 7, wherein A is a fused imidazole ring.

13. (Original) The compound of Claim 4, wherein X is nitrogen and A is a fused imidazole ring.

14. (Previously presented) The compound of Claim 4, wherein R^2 is $-(CH_2)_{0-3}NR'R''$ or $-SO_2NR'R''$, and wherein R' and R" are independently in each occurrence selected from hydrogen, lower alkyl, substituted lower alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, or R' and R" together with the nitrogen to which they are attached may form a 5- to 7- membered ring, optionally incorporating one additional ring heteroatom chosen from N, O, or S.

15. (Previously presented) The compound of Claim 6, wherein R^2 is $-(CH_2)_{0-3}NR'R''$ or $-SO_2NR'R''$, and wherein R' and R" are independently in each occurrence selected from hydrogen, lower alkyl, substituted lower alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, or R' and R" together with the nitrogen to which they are attached may form a 5- to 7- membered ring, optionally incorporating one additional ring heteroatom chosen from N, O, or S.

16. (Original) The compound of Claim 15, wherein Z is -C(O)-.

17. (Canceled).

18. (Previously presented) The compound of Claim 6, wherein R^2 is selected from the groups -C(NH)-NR'R", -N-C(NR')-R", and -N=CR'-NR'R", and wherein R' and R" are independently in each occurrence selected from hydrogen, lower alkyl, substituted lower alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, or R' and R" together with the nitrogen to which they are attached may form a 5- to 7- membered ring, optionally incorporating one additional ring heteroatom chosen from N, O, or S.

19. (Previously presented) The compound of Claim 18, wherein Z is -C(O)-.

20. (Previously presented) A compound of Claim 6, wherein R^2 is aryl or heteroaryl.

21. (Previously presented) A compound of Claim 6, wherein R^2 is alkoxy, cyano, or cyanoalkyl.

22. (Previously presented) The compound of Claim 8, wherein R^2 is $-(CH_2)_{0-3}NR'R''$ or $-SO_2NR'R''$, and wherein R' and R" are independently in each occurrence selected from hydrogen, lower alkyl, substituted lower alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, or R' and R" together with the nitrogen to which they are attached may form a 5- to 7- membered ring, optionally incorporating one additional ring heteroatom chosen from N, O, or S.

23. (Previously presented) The compound of Claim 22, wherein R^2 is -NR'R", and wherein R' and R" are selected from hydrogen or alkyl, or R' and R" taken together with the nitrogen to which they are attached may form a 5- to 7- membered ring, optionally incorporating one additional ring heteroatom chosen from N, O, or S.

24. (Original) The compound of Claim 22, wherein Z is -C(O)-.

25. (canceled).

26. (Previously presented) The compound of Claim 13, wherein R^2 is $-(CH_2)_{0-3}NR'R''$ or $-SO_2NR'R''$, and wherein R' and R" are independently in each occurrence selected from hydrogen, lower alkyl, substituted lower alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, or R' and R" together with the nitrogen to which they are attached may form a 5- to 7- membered ring, optionally incorporating one additional ring heteroatom chosen from N, O or S.

27. (Original) The compound of Claim 26, wherein Z is -C(O)-.

28 (Canceled).

29. (Previously presented) The compound of Claim 1, wherein the compound is:
6,7-dimethoxy-2-[5-(4-methoxy-phenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-3H-quinazolin-4-one;

6,7-dimethoxy-2-[7-(4-methoxy-phenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-3H-quinazolin-4-one;

6,7-dimethoxy-2-(4-morpholin-4-yl-5,8-dihydro-6*H*-pyrido[3,4-*d*]pyrimidin-7-yl)-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-(5-pyridin-3-yl-3,4-dihydro-1*H*-isoquinolin-2-yl)-3*H*-quinazolin-4-one;

2-(4-benzylamino-5,8-dihydro-6*H*-pyrido[3,4-*d*]pyrimidin-7-yl)-6,7-dimethoxy-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-(5-pyrrolidin-1-yl-3,4-dihydro-1*H*-isoquinolin-2-yl)-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-(5-pyridin-4-yl-3,4-dihydro-1*H*-isoquinolin-2-yl)-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-(5-pyrimidin-5-yl-3,4-dihydro-1*H*-isoquinolin-2-yl)-3*H*-quinazolin-4-one;

2-(6,7-dimethoxy-4-oxo-1,4-dihydro-quinazolin-2-yl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonic acid (2-pyridin-2-yl-ethyl)-amide;

2-(6,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline-5-carbonitrile;

6,7-dimethoxy-2-[5-(1*H*-pyrrol-2-yl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3*H*-quinazolin-4-one;

2-[5-(1*H*-imidazol-2-yl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-6,7-dimethoxy-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-[4-(4-methyl-piperazin-1-yl)-5,8-dihydro-6*H*-pyrido[3,4-*d*]pyrimidin-7-yl]-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-{4-[(2-methoxy-ethyl)-methyl-amino]-5,8-dihydro-6*H*-pyrido[3,4-*d*-pyrimidin-7-yl}-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-[5-(morpholine-4-sulfonyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-(4-piperidin-1-yl-5,8-dihydro-6*H*-pyrido[3,4-*d*]pyrimidin-7-yl)-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-[5-(1-morpholin-4-yl-methanoyl)-3,4-dihydro-3*H*-isoquinolin-2-yl]-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-(1-phenyl-1,4,6,7-tetrahydro-imidazo[4,5-*c*]pyridin-5-yl)-3*H*-quinazolin-4-one;

2-[1-(4-chloro-phenyl)-1,4,6,7-tetrahydro-imidazo[4,5-*c*]pyridin-5-yl]-6,7-dimethoxy-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-(1-naphthalen-2-yl-1,4,6,7-tetrahydro-imidazo[4,5-*c*]pyridin-5-yl)-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-[1-(4-methoxy-phenyl)-1,4,6,7-tetrahydro-imidazo[4,5-*c*]pyridin-5-yl]-3*H*-quinazolin-4-one;

2-[1-(3-chloro-phenyl)-1,4,6,7-tetrahydro-imidazo[4,5-*c*]pyridin-5-yl]-6,7-dimethoxy-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-(1-*m*-tolyl-1,4,6,7-tetrahydro-imidazo[4,5-*c*]pyridin-5-yl)-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-(3-phenyl-5,6-dihydro-8*H*-imidazo[1,5-*a*]pyrazin-7-yl)-1*H*-quinazolin-4-one;

2-(3-cyclohexyl-5,6-dihydro-8*H*-imidazo[1,5-*a*]pyrazin-7-yl)-6,7-dimethoxy-1*H*-quinazolin-4-one;

6,7-dimethoxy-2-(1,3,4,9-tetrahydro-β-carbolin-2-yl)-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-(6-methoxy-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-(7-methylsulfanyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3*H*-quinazolin-4-one;

2-(3,4-dihydro-1*H*-2,7,10-triaza-anthracen-2-yl)-6,7-dimethoxy-3*H*-quinazolin-4-one;

N-[2-(6,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-1,2,3,4-tetrahydro-isoquinolin-5-yl]-cyclopentanecarboxamidine;

6,7-dimethoxy-2-(5-morpholin-4-ylmethyl-3,4-dihydro-1*H*-isoquinolin-2-yl)-3*H*-quinazolin-4-one;

6,7-dimethoxy-2-(5-piperidin-1-ylmethyl-3,4-dihydro-1*H*-isoquinolin-2-yl)-3*H*-quinazolin-4-one;

2-[5-(4,5-dihydro-1*H*-imidazol-2-ylamino)-3,4-dihydro-1*H*-isoquinolin-2-yl]-6,7-dimethoxy-3*H*-quinazolin-4-one;

N-[2-(6,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-1,2,3,4-tetrahydro-isoquinolin-5-yl]-cyclobutanecarboxamidine;

N-[2-(6,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-1,2,3,4-tetrahydro-isoquinolin-5-yl]-butyramidine;
N-[2-(6,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-1,2,3,4-tetrahydro-isoquinolin-5-yl]-*N*,*N*-dimethyl-formamidine;
6,7-dimethoxy-2-[5-(1-methyl-4,5-dihydro-3*H*-pyrrol-2-ylamino)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3*H*-quinazolin-4-one; or
2-[5-(4,5-dihydro-3*H*-pyrrol-2-ylamino)-3,4-dihydro-1*H*-isoquinolin-2-yl]-6,7-dimethoxy-3*H*-quinazolin-4-one; or a pharmaceutically-acceptable salt thereof.

30. (Original). A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Claim 1 in admixture with at least one pharmaceutically acceptable carrier.

31. (Canceled)

32. (Previously presented) A method of treating a subject having a disease state that is alleviated by treatment with an alpha-1A/B adrenoceptor antagonist, which method comprises administering to the subject a therapeutically effective amount of at least one compound of Claim 1.

33. (Canceled)

34. (Previously presented) The method of Claim 32 wherein the disease state comprises disorders and symptoms of the urinary tract.

35. (Previously presented) The method of Claim 32 wherein the disease state comprises improvement of sexual dysfunction.

36. (Previously presented) The method of Claim 32 wherein the disease state comprises benign prostatic hypertrophy and the irritative symptoms associated with benign prostatic hypertrophy.

37. (Previously presented) The method of Claim 32 wherein the disease state comprises pain.

38. (Original) The method of Claim 37 wherein the disease state comprises inflammatory pain, neuropathic pain, cancer pain, acute pain, chronic pain, or complex regional pain syndromes.

39. (Canceled)

40. (Currently amended) A compound having the formula,



wherein:

X is carbon or nitrogen;

Y is carbon; and X-Y considered together are two adjoining atoms of the ring A, said ring being selected from a fused benzo, pyrrolyl, imidazolyl, pyridyl, or pyrimidinyl ring; wherein when X is nitrogen, the bond between atoms X and Y is a single bond, and when X is carbon, the bond between atoms X and Y is double bond; and

R^2, R^3, and R^4 are each independently in each occurrence selected from:

hydrogen; lower alkyl;

hydroxy; hydroxyalkyl; alkoxy; alkoxyalkyl;

halo; haloalkyl; cyano; cyanoalkyl;

cyclopentyl, cyclohexyl, or cycloheptyl;

phenyl, phenyl(lower alkyl), pyridyl, pyridyl(lower alkyl) pyrimidinyl, pyrimidinyl(lower alkyl), pyrazinyl, pyrazinyl (lower alkyl), pyrrolyl, pyrrolyl(lower alkyl), imidazolyl, imidazolyl(lower alkyl), and napthyl, each of said aryl and heteroaryl rings in turn optionally substituted with one to two halogen, lower alkoxy, lower alkyl, trifluoromethyl, methylthiol, and/or amino;

morpholinyl, morpholinyl(lower alkyl), piperidinyl, piperidinyl(lower alkyl), piperazinyl, piperazinyl(lower alkyl) pyrrolidinyl, pyrrolidinyl(lower alkyl), imidazolidinyl, imidazolidinyl(lower alkyl), tetrahydrofuryl, tetrahydofuryl(lower alkyl), and 1-H-pyrimidine-2,4-dione, each of said heterocyclic rings in turn optionally substituted with one to two of hydroxy, oxo, lower alkoxy, hydroxy(lower alkyl), and/or phenyl, said phenyl in turn optionally substituted with one or two substituents selected from the group consisting of lower alkyl, halogen, cyano and lower alkoxy;

$-(CH_2)_{0-3}NR'R''$; $-SO_2NR'R''$; -C(O)R'; -C(=NH)-NR'R"; -N-C(=NH)-R"; and -N=CR'-NR'R"; and ~~N-R'";~~

or R^2 and R^3 taken together form a fused pyridyl or a methylenedioxy or ethylenedioxy group to form a fused heterocyclic ring;

with the proviso that if A is a benzene ring, at least one of R^2, R^3 or R^4 is not hydrogen;

R and R" are individually selected from hydrogen, lower alkyl, lower alkoxy, hydroxyalkyl, phenyl, phenyl(lower alkyl), pyridyl, pyridyl(lower alkyl), pyrrolidinyl, furyl, imidazolidinyl, piperidinyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, morpholinyl, said rings in turn optionally substituted with lower alkyl, lower alkoxy, cyano(lower alkyl), 5,6-dihydro-2*H*-thiazin-3-yl;

or alternatively, R' and R" together with the nitrogen to which they are attached may form a piperidinyl or morpholinyl ring optionally substituted with one or two substituents selected from the group consisting of lower alkyl, lower alkoxy, cyano, or cyano(lower alkyl) ~~; and~~

R'" is ~~selected from pyrrolidinyl and piperidinyl in turn optionally substituted with up to one lower alkyl, lower alkoxy, cyano~~, or cyano(~~lower alkyl~~).

41. (Currently amended) A compound according to claim [[41]] 40, in which X is carbon and A is a fused aryl, pyridyl, or pyrimidinyl ring.